Travere

Sequenex partners with MedTech Innovator, a leading healthcare startup accelerator

Sequenex Announces Partnership with MedTech Innovator, Industry’s Leading Startup Accelerator Sequenex announced its partnership with MedTech Innovator (MTI), the world’s largest accelerator of medical technology companies. MedTech Innovator matches healthcare industry leaders with innovative early-stage medtech companies for mentorship and…

Read MoreSequenex partners with MedTech Innovator, a leading healthcare startup accelerator
Chemical

Chemical Reduction Solutions expands partnership with Simoniz USA to commercialize nanobubble technology in the car wash industry

Chemical Reduction Solutions LLC Expands Partnership with Simoniz USA Inc. to Exclusively Commercialize Nanobubble Technology in the Car Wash Industry Chemical Reduction Solutions LLC (“CRS”), a developer of hydrodynamic cavitation-based nanobubble technology, today announced an expanded partnership with Simoniz USA…

Read MoreChemical Reduction Solutions expands partnership with Simoniz USA to commercialize nanobubble technology in the car wash industry
Litmys

SK Capital completes sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG

SK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG Affiliates of funds advised by SK Capital Partners, LP a private investment firm focused on the life sciences, specialty materials, and ingredients sectors announced today…

Read MoreSK Capital completes sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG
Arrowhead

Arrowhead wins Australian approval for REDEMPLO® (plozasiran) for FCS treatment

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals, Inc. announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine,…

Read MoreArrowhead wins Australian approval for REDEMPLO® (plozasiran) for FCS treatment
Nebius

Nebius to acquire Eigen AI, boosting Nebius Token Factory as a frontier inference platform

Nebius Agrees to Acquire Eigen AI, Strengthening Nebius Token Factory as a Frontier Inference Platform Nebius the AI cloud company, announced an agreement to acquire Eigen AI, a leading inference and model optimization company. The acquisition will strengthen Nebius Token Factory…

Read MoreNebius to acquire Eigen AI, boosting Nebius Token Factory as a frontier inference platform
FDA Advisory Committee backs TRUQAP®

FDA Advisory Committee backs TRUQAP® (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer

TRUQAP® (capivasertib)recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy…

Read MoreFDA Advisory Committee backs TRUQAP® (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer
ProNatural Brands

ProNatural Brands reports strong growth, Amazon expansion, and rising demand for natural cleaning products

ProNatural Brands Announces Strong Growth, Amazon Expansion, and Accelerating Consumer Demand for Natural Cleaning Solutions ProNatural Brands announced continued strong growth and expanding market momentum as demand rises for safer, more sustainable cleaning and disinfecting solutions. Founded in 2012, ProNatural…

Read MoreProNatural Brands reports strong growth, Amazon expansion, and rising demand for natural cleaning products
Availity’s first Abrasion Index pinpoints where

Availity’s first Abrasion Index pinpoints where payer-provider friction hits healthcare hardest

Availity’s Inaugural Abrasion Index Reveals Where Payer-Provider Friction Hits Healthcare Hardest Availity®, the nation’s largest health information network, today released its first annual Availity Abrasion Index, a research-informed report that measures where administrative friction between health plans and providers is highest…

Read MoreAvaility’s first Abrasion Index pinpoints where payer-provider friction hits healthcare hardest
Sunnybrook

Sunnybrook Health Sciences Centre announces a $41 million gift to strengthen Canada’s global leadership in clinical trials

Sunnybrook Announces $41-Million Gift to Advance Canada’s Global Leadership in Clinical Trials Sunnybrook Health Sciences Centre is proud to announce a $41M philanthropic investment in Sunnybrook Clinical Trials. The investment expands dedicated infrastructure, capacity and expertise across Sunnybrook to optimize how clinical…

Read MoreSunnybrook Health Sciences Centre announces a $41 million gift to strengthen Canada’s global leadership in clinical trials
Compass

Compass Pathways secures FDA rolling NDA review and earns Commissioner’s National Priority Voucher

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner’s National Priority Voucher Compass Pathways plc a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration…

Read MoreCompass Pathways secures FDA rolling NDA review and earns Commissioner’s National Priority Voucher
Bruker Unveils MyGenius PRO® High

Bruker Unveils MyGenius PRO® High-Throughput Molecular Diagnostics System at ESCMID 2026

Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain…

Read MoreBruker Unveils MyGenius PRO® High-Throughput Molecular Diagnostics System at ESCMID 2026